RPS6KB1 (Ab-389) Antibody

What is the target specificity of RPS6KB1 (Ab-389) Antibody?

RPS6KB1 (Ab-389) Antibody is a rabbit polyclonal antibody that specifically recognizes the phosphorylated threonine 389 region of RPS6KB1 (ribosomal protein S6 kinase beta-1, also known as p70 S6K1) . The antibody was generated using a synthetic phosphopeptide corresponding to residues surrounding T389 of human p70S6K1 (sequence: G-F-T-Y-V) . This phosphorylation site is particularly important as it serves as a critical regulatory site that reflects mTORC1 activation status. The antibody has been validated for reactivity with human, mouse, and rat samples .

What techniques can RPS6KB1 (Ab-389) Antibody be used for?

The RPS6KB1 (Ab-389) Antibody has been validated for multiple experimental applications:

Researchers should note that optimal dilutions may need to be determined empirically for specific experimental conditions and sample types .

How should samples be prepared for optimal detection of phosphorylated RPS6KB1 (T389)?

For optimal detection of phosphorylated RPS6KB1 at T389:

• Lysis buffer components: Use phosphatase inhibitor-containing buffers (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate) to preserve phosphorylation status.

• Sample handling: Process samples rapidly and maintain at cold temperatures (4°C) throughout preparation to prevent dephosphorylation.

• Stimulation conditions: For positive controls, treat cells with insulin (0.01U/ml) as demonstrated in the antibody validation studies .

• Loading controls: Include both total RPS6KB1 and phospho-specific detection for accurate interpretation of phosphorylation status.

• Blocking conditions: Verify specificity by including a phospho-peptide blocking control, which should abolish signal as demonstrated in validation studies .

How can researchers differentiate between total RPS6KB1 and its phosphorylated form?

To effectively differentiate between total and phosphorylated RPS6KB1:

• Dual antibody approach: Use both phospho-specific (T389) and total RPS6KB1 antibodies on parallel blots or sequential detection after stripping.

• Mobility shift analysis: Phosphorylated RPS6KB1 often displays a slight upward shift in molecular weight (typically appearing as a band at ~70-85 kDa) compared to the unphosphorylated form .

• Phosphatase treatment controls: Treat a portion of your samples with lambda phosphatase to remove phosphorylation, then compare with untreated samples.

• Stimulation-inhibition experiments: Include samples with known pathway activators (insulin, growth factors) and inhibitors (rapamycin, LY2584702) to establish phosphorylation dynamics .

Research has shown that in some disease states, particularly in cancer, the ratio of phosphorylated to total RPS6KB1 provides more meaningful biological information than either measurement alone .

How does the phosphorylation of RPS6KB1 at T389 correlate with downstream signaling events?

Phosphorylation of RPS6KB1 at T389 serves as a critical node in cellular signaling:

• mTORC1 signaling: T389 phosphorylation is directly mediated by mTORC1 and serves as a reliable readout for mTORC1 activity .

• S6 phosphorylation: Activated RPS6KB1 (phosphorylated at T389) directly phosphorylates ribosomal protein S6 at S235/S236, triggering increased protein translation .

• Feedback regulation: Activated RPS6KB1 participates in feedback regulation of both mTORC1 and mTORC2, creating a complex signaling network .

• Cell survival signaling: Research shows that phosphorylated RPS6KB1 promotes cell survival by phosphorylating the pro-apoptotic protein BAD, suppressing its apoptotic function .

• Metabolic control: RPS6KB1 phosphorylates CAD (carbamoyl-phosphate synthetase 2), activating pyrimidine biosynthesis downstream of mTOR .

Studies in NSCLC have demonstrated that the phosphorylation status of RPS6KB1 at T389, rather than total RPS6KB1 expression, correlates with adverse prognosis in patients .

What are the potential pitfalls when interpreting RPS6KB1 phosphorylation data?

Researchers should be aware of several challenges when interpreting RPS6KB1 phosphorylation data:

• Multiple phosphorylation sites: RPS6KB1 has several phosphorylation sites (T389, T412, T421, S424) that can influence antibody reactivity and protein function. Ensure you are using the appropriate antibody for your specific research question .

• Antibody cross-reactivity: Some phospho-specific antibodies may recognize similar phosphorylation motifs in related kinases. Always include appropriate controls .

• Alternative splicing effects: Research has shown that RPS6KB1 undergoes alternative splicing, producing short isoforms that are overexpressed in certain cancers. These isoforms may affect epitope accessibility and alter interpretation of results .

• Rapid dephosphorylation: The phosphorylation at T389 is highly labile and can be rapidly lost during sample preparation. Inconsistent results may reflect technical variations rather than biological differences .

• Context-dependent signaling: The relationship between RPS6KB1 phosphorylation and biological outcomes can vary drastically between cell types and disease states .

How can RPS6KB1 (Ab-389) Antibody be used to study cancer biology?

The RPS6KB1 (Ab-389) Antibody has proven valuable in cancer research:

What methodological approaches can distinguish between direct and indirect effects on RPS6KB1 phosphorylation?

To determine whether changes in RPS6KB1 phosphorylation are direct or indirect:

• Kinase inhibitor panels: Utilize specific inhibitors of mTOR (rapamycin, torin), PI3K (wortmannin, LY294002), and other upstream kinases to delineate the pathway responsible for observed phosphorylation changes.

• Genetic approaches: Employ CRISPR/Cas9 or siRNA-mediated knockdown of upstream regulators to establish the hierarchy of signaling events leading to RPS6KB1 phosphorylation.

• In vitro kinase assays: Purified kinases (e.g., mTOR complex) can be used with recombinant RPS6KB1 to confirm direct phosphorylation.

• Phosphosite mutant expression: Express T389A phospho-deficient RPS6KB1 mutants to confirm specificity of observed effects.

• Proximity ligation assays: These can detect direct protein-protein interactions between RPS6KB1 and potential upstream kinases in situ.

Research has demonstrated that the long S6K1 variant (Iso-1) and short isoforms have opposing effects on transformation and tumor formation, highlighting the importance of isoform-specific analysis when studying RPS6KB1 signaling .

How does RPS6KB1 phosphorylation at T389 compare with phosphorylation at other sites?

Multiple phosphorylation sites on RPS6KB1 serve distinct regulatory functions:

Research indicates that while multiple phosphorylation events are required for full activation of RPS6KB1, T389 phosphorylation serves as the critical step that determines kinase activity . Studies in NSCLC have specifically demonstrated that T389 phosphorylation, rather than total RPS6KB1 expression or other phosphorylation sites, most strongly correlates with clinical outcomes .

What are current technical challenges in measuring dynamic RPS6KB1 phosphorylation in live cells?

Researchers face several technical challenges when attempting to measure dynamic RPS6KB1 phosphorylation:

• Temporal resolution: T389 phosphorylation can change rapidly (within minutes) after stimulation or inhibition, requiring sampling techniques with appropriate temporal resolution.

• Phosphorylation-specific biosensors: Development of FRET-based sensors for specific RPS6KB1 phosphorylation sites is technically challenging but would enable real-time monitoring in live cells.

• Single-cell vs. population averages: Traditional methods like Western blotting provide population averages, potentially masking important cell-to-cell variations that could be captured with techniques like phospho-flow cytometry.

• Compartment-specific activation: RPS6KB1 can localize to different subcellular compartments (cytoplasm, nucleus, mitochondrial outer membrane ), and phosphorylation may occur differentially in these locations.

• Multisite phosphorylation dynamics: The temporal relationship between phosphorylation at T389 and other sites (T229, T421/S424) adds complexity to interpreting dynamic measurements.

Advanced researchers are addressing these challenges through the development of phosphorylation-specific intracellular nanobodies and improved phospho-proteomics methodologies that allow temporal profiling of multiple phosphorylation events simultaneously.

What are common sources of false negative results when using RPS6KB1 (Ab-389) Antibody?

False negative results may occur due to:

• Rapid dephosphorylation: Insufficient or delayed addition of phosphatase inhibitors during sample preparation can lead to loss of T389 phosphorylation.

• Inadequate stimulation: Basal levels of T389 phosphorylation may be low in unstimulated cells; consider treatment with insulin (0.01U/ml) as a positive control .

• Incorrect antibody dilution: The recommended dilutions vary by application (WB: 1:500-1:1000; IF: 1:100-1:200); suboptimal concentrations may yield weak signal .

• Buffer incompatibility: Certain detergents or buffer components may interfere with epitope recognition; follow validated lysis protocols.

• Epitope masking: Protein-protein interactions or conformational changes may mask the T389 epitope in certain contexts.

To troubleshoot, researchers should:

• Include positive controls (insulin-stimulated cells)

• Compare multiple lysis methods

• Test different antibody concentrations

• Consider using enhanced chemiluminescence substrates for Western blot detection

How can the specificity of RPS6KB1 (Ab-389) Antibody be validated in experimental settings?

To validate antibody specificity:

• Peptide competition assay: Pre-incubate the antibody with the immunizing phosphopeptide before application to samples. This should abolish specific signal, as demonstrated in the antibody validation studies .

• Phosphatase treatment: Treat a portion of your lysate with lambda phosphatase to remove phosphorylation and confirm loss of signal.

• Pharmacological inhibition: Treat cells with mTOR inhibitors (rapamycin, Torin1) to reduce T389 phosphorylation, which should diminish signal intensity.

• Genetic approaches: Use RPS6KB1 knockout or knockdown models as negative controls, or express phospho-deficient mutants (T389A).

• Multiple antibody comparison: Utilize antibodies from different suppliers targeting the same phosphorylation site to confirm consistent patterns.

Research has demonstrated the specificity of phospho-T389 antibodies in immunohistochemical staining of NSCLC tissues, where phospho-peptide blocking eliminated specific staining .

What considerations are important when selecting control samples for RPS6KB1 phosphorylation studies?

Appropriate controls are critical for RPS6KB1 phosphorylation studies:

• Positive controls:

  • Insulin-stimulated cells (0.01U/ml) for acute T389 phosphorylation

  • Cell lines with constitutive mTOR activation (e.g., those lacking TSC1/2)

  • Tissues known to have high basal mTORC1 activity (e.g., liver)

• Negative controls:

  • Serum-starved cells to establish baseline phosphorylation

  • mTOR inhibitor-treated samples (rapamycin, Torin1)

  • Samples treated with LY2584702, a specific RPS6KB1 inhibitor

• Experimental design considerations:

  • Include time-course analyses to capture phosphorylation dynamics

  • Measure both phosphorylated and total RPS6KB1 in parallel

  • Monitor downstream targets (S6 phosphorylation) to confirm functional activation

In clinical studies, adjacent non-cancerous tissues serve as important controls, as demonstrated in NSCLC research showing significant differences in phospho-RPS6KB1 between tumor and normal tissues (61.25% vs. 41.86%, p=0.004) .

How does alternative splicing of RPS6KB1 affect antibody recognition and experimental interpretation?

Research has revealed important implications of RPS6KB1 alternative splicing:

• Isoform diversity: Studies have identified multiple S6K1 isoforms resulting from alternative splicing, including the long variant (Iso-1) and shorter isoforms .

• Epitope conservation: The phosphorylation site at T389 may be preserved across some but not all isoforms, potentially affecting antibody recognition.

• Functional divergence: Research has shown that short isoforms of S6K1 can activate mTORC1 and promote oncogenic transformation, while the long isoform (Iso-1) may have tumor suppressor activity .

• Expression patterns: Short isoforms are overproduced in breast cancer cell lines and tumors, creating a potential confound when interpreting phosphorylation data across different samples .

• Experimental considerations: Researchers should consider running gels that can resolve different isoforms and be aware that phosphorylation patterns may differ between isoforms.

These findings suggest that researchers studying RPS6KB1 phosphorylation should consider isoform-specific analyses to fully understand the biological significance of their observations .

What is the relationship between RPS6KB1 phosphorylation at T389 and clinical outcomes in cancer?

Clinical research has established important correlations between RPS6KB1 phosphorylation and cancer outcomes:

The data suggest that phospho-RPS6KB1 status may serve as both a prognostic biomarker and a potential therapeutic target in multiple cancer types .

How can multiplexed phospho-proteomic approaches enhance RPS6KB1 signaling research?

Advanced phospho-proteomic approaches offer several advantages for RPS6KB1 research:

• Pathway context: Simultaneous measurement of multiple phosphorylation sites on RPS6KB1 (T389, T229, T421/S424) along with upstream regulators and downstream targets provides comprehensive pathway visualization.

• Temporal dynamics: Modern phospho-proteomics can capture rapid signaling changes across multiple timepoints, revealing the sequence of phosphorylation events.

• Novel interaction discovery: Affinity purification of phosphorylated RPS6KB1 followed by mass spectrometry can identify novel binding partners that may be phosphorylation-dependent.

• Isoform-specific analysis: Proteomics approaches can distinguish between different RPS6KB1 isoforms and their phosphorylation patterns, addressing the complexity introduced by alternative splicing .

• Clinical application: Phospho-proteomic profiling of patient samples may identify patterns of pathway activation that correlate with disease progression or treatment response beyond single biomarkers.

These approaches have the potential to resolve current contradictions in RPS6KB1 research, such as the dual oncogenic and tumor suppressor roles proposed for different isoforms .